{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ELX%2FTEZ%2FIVA", "query": { "intervention": "ELX/TEZ/IVA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ELX%2FTEZ%2FIVA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T06:24:16.098Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04058353", "title": "A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 271, "start_date": "2019-08-28", "completion_date": "2020-06-12", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058353" }, { "nct_id": "NCT04923464", "title": "A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-06-30", "completion_date": "2021-12-20", "has_results": false, "last_update_posted_date": "2022-01-19", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 11, "location_summary": "Denver, Colorado • New Haven, Connecticut • Orlando, Florida + 8 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923464" }, { "nct_id": "NCT05076149", "title": "A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121/TEZ/D-IVA", "type": "DRUG" }, { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo (matched to VX-121/TEZ/D-IVA)", "type": "DRUG" }, { "name": "Placebo (matched to ELX/TEZ/IVA)", "type": "DRUG" }, { "name": "Placebo (matched to IVA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 597, "start_date": "2021-10-27", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05076149" }, { "nct_id": "NCT03227471", "title": "A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "VX-445", "type": "DRUG" }, { "name": "Matched Placebo", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2017-01-23", "completion_date": "2018-03-27", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 26, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227471" }, { "nct_id": "NCT04043806", "title": "A Study Evaluating the Long-term Safety of VX-445 Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 458, "start_date": "2019-08-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04043806" }, { "nct_id": "NCT05153317", "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 71, "start_date": "2022-01-17", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 13, "location_summary": "Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153317" }, { "nct_id": "NCT05033080", "title": "A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121/TEZ/D-IVA", "type": "DRUG" }, { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo (matched to VX-121/TEZ/D-IVA)", "type": "DRUG" }, { "name": "Placebo (matched to ELX/TEZ/IVA)", "type": "DRUG" }, { "name": "Placebo (matched to IVA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 435, "start_date": "2021-09-14", "completion_date": "2023-11-21", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05033080" }, { "nct_id": "NCT03691779", "title": "Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 71, "start_date": "2018-10-02", "completion_date": "2020-08-07", "has_results": true, "last_update_posted_date": "2021-10-22", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 13, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691779" }, { "nct_id": "NCT04840862", "title": "Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Drug Drug Interaction" ], "interventions": [ { "name": "Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]", "type": "DRUG" }, { "name": "Rifabutin 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2022-05-09", "completion_date": "2024-05-30", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840862" }, { "nct_id": "NCT04058366", "title": "Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 251, "start_date": "2019-12-05", "completion_date": "2022-12-16", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-09-23T06:24:16.098Z", "location_count": 33, "location_summary": "Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058366" } ] }